Furthermore, under this MCI umbrella—in combination with biomarkers that differentiate AD risk—key “at risk” sub-populations warrant research priority in future RCTs: (1) individuals with the APOE-ε4 genotype; and (2) individuals with comorbid conditions including diabetes, cardiovascular disease, and stroke. Here, APOE is linked to cardiovascular disorder.